Clinical experience of MEK inhibitors in cancer therapy

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

ras oncogenes in human cancer: a review.

1989 • 5,116 citations

Specificity and mechanism of action of some commonly used protein kinase inhibitors

2000 • 4,109 citations

PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo

1995 • 3,456 citations

Targeting RAS signalling pathways in cancer therapy

2003 • 3,105 citations

Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase

1998 • 3,026 citations

A synthetic inhibitor of the mitogen-activated protein kinase cascade.

1995 • 2,723 citations

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.

2003 • 1,490 citations

Transformation of Mammalian Cells by Constitutively Active MAP Kinase Kinase

1994 • 1,370 citations

BRAF mutation predicts sensitivity to MEK inhibition

2005 • 1,312 citations

Targeting the mitogen-activated protein kinase cascade to treat cancer

2004 • 1,093 citations

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo

1999 • 970 citations

BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer

2005 • 956 citations

Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma

2003 • 829 citations

Understanding Ras: ‘it ain’t over ’til it’s over’

2000 • 785 citations

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

1999 • 688 citations

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance

2006 • 638 citations

Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer

2004 • 631 citations

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

2004 • 588 citations

Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor

2007 • 556 citations

Germline Mutations in Genes Within the MAPK Pathway Cause Cardio-facio-cutaneous Syndrome

2006 • 549 citations

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

2006 • 453 citations

High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.

2003 • 424 citations

MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-XL, and Mcl-1 and promotes survival of human pancreatic cancer cells

2000 • 403 citations

MEK inhibitors: The chemistry and biological activity of U0126, its analogs, and cyclization products

1998 • 402 citations

Phase I and Pharmacodynamic Study of the Oral MEK Inhibitor CI-1040 in Patients With Advanced Malignancies

2005 • 400 citations

Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells.

1992 • 370 citations

Anti-Inflammatory Effects of Mitogen-Activated Protein Kinase Kinase Inhibitor U0126 in an Asthma Mouse Model

2004 • 262 citations

Membrane Association and Targeting of Prenylated Ras-like GTPases

1998 • 259 citations

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR Inhibitors

2005 • 116 citations

A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer

2005 • 91 citations

Identification of a Novel Mitogen-Activated Protein Kinase Kinase Activation Domain Recognized by the Inhibitor PD 184352

2002 • 68 citations

Altered MAP kinase (ERK1,2) regulation in primary cultures of mammary tumor cells: elevated basal activity and sustained response to EGF

1999 • 58 citations

Central Role of Fas-associated Death Domain Protein in Apoptosis Induction by the Mitogen-activated Protein Kinase Kinase Inhibitor CI-1040 (PD184352) in Acute Lymphocytic Leukemia Cells in Vitro

2003 • 54 citations

Mechanisms of Resistance to STI571 (Imatinib) in Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia

2003 • 52 citations

BAY-43-9006 Bayer/Onyx.

2003 • 51 citations

Pancreatic cancer cells require an EGF receptor-mediated autocrine pathway for proliferation in serum-free conditions

2001 • 46 citations

Pharmacokinetics (PK) and pharmacodynamics (PD) of PD 0325901, a second generation MEK inhibitor after multiple oral doses of PD 0325901 to advanced cancer patients

2005 • 28 citations

Susceptibility to cell death induced by blockade of MAPK pathway in human colorectal cancer cells carrying Ras mutations is dependent on p53 status

2004 • 19 citations

Preclinical development of ARRY-142886, a potent and selective MEK inhibitor

2004 • 17 citations